Abciximab, Clopidogrel and Percutaneous Coronary Intervention in Acute Coronary Syndrome (ISAR-REACT-2)
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Adnan Kastrati, MD
Deutsches Herzzentrum Muenchen
Principal Investigator - Albert Schomig, MD
Deutsches Herzzentrum Muenchen
Study Chair - Peter B Berger, MD
Duke Clinical Research Institute
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
5 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Instituto Dante Pazzanese de Cardiologia
São Paulo, Brazil
- Herz-Zentrum
Bad Krozingen, Germany
- Deutsches Herzzentrum Muenchen
Munich, Germany
- First Medizinische Klinik, Klinikum Rechts Der Isar
Munich, Germany
- St. Antonius Ziekenhuis Hospital
Nieuwegein, Netherlands
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 31 Mar 2003
- Primary completion
- 31 Jan 2006
- Completion
- 31 Jan 2006
- Last update posted
- 15 Apr 2008
- Registered enrollment
- 2,022
- Registry id
- NCT00133003
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.